The history of Endo can be traced back to 1920 to a family-run pharmaceutical company
originally called Intravenous Products of America, Inc. In 1935 Intravenous Products
of America, Inc. changed its name to Endo Products.
In 1950, PERCODAN® was launched.
In 1970, E.I. du Pont de Nemours and Company (DuPont) acquired Endo. In 1971, PERCOCET®
was launched.
In 1994, DuPont Merck reestablished Endo as a separate entity within the company.
This entity was named Endo Laboratories L.L.C. and served as DuPont Merck's generic
division.
Three executives of DuPont Merck acquired certain products from DuPont Merck in
a management buyout for $277 million with financing from Kelso & Company, a
private equity investment firm purchased all of Endo Laboratories L.L.C.'s generic
products along with 12 important brand products, including PERCOCET®
and PERCODAN®.
Net sales: 39.4 millions
Employees: 62
Endo licensed LIDODERM® from Hind Healthcare.
Net sales: 108.4 millions
Employees: 70
Endo launched three new strengths of its leading brand-name drug PERCOCET®.
After receiving FDA approval, Endo launched LIDODERM® as its first new
proprietary, patented product.
Net sales: 135.5 millions
Employees: 92
Endo Pharmaceuticals acquired Algos Pharmaceutical Corporation through a merger.
As a result of this merger, Endo Pharmaceuticals became a publicly traded company,
under the NASDAQ symbol ENDP.
Net sales: 197.4 millions
Employees: 135
Endo receives FDA approval for new PERCOCET® strengths (7.5/325 and 10/325
oxycodone/acetaminophen).
Net sales: 252 millions
Employees: 167
Endo established its first internal sales force when it converted the contract specialty
sales force and district managers into full-time employees to concentrate sales
efforts.
Endo reached $1 billion dollars in cumulative sales.
Net sales: 399 millions
Employees: 277
Endo further expands its internal sales force by converting the contract pharma
sales force, district managers and regional directors to full-time Endo employees.
Net sales: 595.6 millions
Employees: 492
Endo entered into an agreement with Vernalis for the exclusive rights to market
FROVA® in North America. Launched in the U.S. in June 2002, FROVA is
indicated for the acute treatment of migraine headaches in adults.
Net sales: 615.1 millions
Employees: 594
Endo Pharmaceuticals acquired exclusive licenses from DURECT Corporation to develop
and commercialize a seven-day transdermal sufentanil patch (EN3270) intended for
moderate-to-severe chronic pain.
Net sales: 820.2 millions
Employees: 710
Endo received FDA approval for OPANA® and OPANA® ER, which
represented the first internally developed NDAs to be granted FDA approval.
Endo Pharmaceuticals acquires RxKinetix, Inc. through an acquisition. The acquisition
broadens Endo pipeline with supportive care oncology products, including EN3285,
a topical oral-rinse for the prevention of oral mucositis.
Net sales: 909.7 millions
Employees: 1,024
Endo celebrated its 10-year anniversary.
Roger Kimmel appointed chairman of the Board; Carol Ammon retired.
Endo entered into a license and development agreement with Alexza Pharmaceuticals,
Inc. for the exclusive clinical development and commercialization rights in North
America for Alexza's AZ-003/ EN3294. Currently in Phase I, clinical development,
AZ-003 is a hand-held drug device system that uses Alexza's proprietary Staccato®
system inhalation technology to deliver fentanyl for the treatment of breakthrough
pain in cancer and non-cancer patients.
Net sales: 1,085.6 millions
Employees: 1,208
Endo entered into a licensing agreement with Novartis to obtain the exclusive U.S.
marketing rights for the prescription medicine Voltaren® Gel (diclofenac
sodium topical gel) 1%. Voltaren Gel received regulatory approval in October 2007
from the U.S. Food and Drug Administration, becoming the first topical prescription
treatment for use in treating pain associated with osteoarthritis and the first
new product approved in the U.S. for osteoarthritis since 2001.
David Holveck is named President, Chief Executive Officer and a Director of Endo.
A new executive team is created to take Endo to the next level.
On March 23, 2009, Endo Pharmaceuticals successfully completed its acquisition of
Indevus Pharmaceuticals, Inc. Indevus brought us multiple marketed products that
enhance revenue growth, a specialized infrastructure focused in urology, endocrinology
and oncology, and a strong drug-development pipeline.
Endo launches VALSTAR¯ for the treatment of bladder cancer
On July 15,2010, HealthTronics, Inc. becomes a wholly owned subsidiary of Endo Pharmaceuticals.
On November 4, 2010, Penwest Pharmaceuticals becomes a wholly owned subsidiary of
Endo Pharmaceuticals.
On December 1, 2010, Qualitest Pharmaceuticals becomes a wholly owned subsidiary
of Endo Pharmaceuticals.
On December 29, 2010, the U.S. Food and Drug Administration approved FORTESTA™
Gel.
On January 28, 2011, Endo enters into a collaboration agreement with Orion Corporation
for the discovery, development and commercialization of assets in Oncology.
On March 3, 2011, Endo Launches FORTESTA™ (Testosterone) Gel.
On June 20, 2011 American Medical Systems (AMS) becomes a wholly owned subsidiary
of Endo Pharmaceuticals.
No content!
